Next-Gen Cytokine Therapeutics Summit

Next-Gen Cytokine Therapeutics Summit

November 3rd, 2020 | EST Timezone

Advancing The Next Generation Of Cytokine Therapeutics

Re-engineered for Online

Find Out More Agenda

2020 Partners

Founding Partner
Founding Partner

Nektar Therapeutics is a research-based development stage biopharmaceutical company that discovers and develops innovative medicines in areas of high unmet medical need. Our R&D pipeline of new investigational drugs includes treatments for cancer and auto-immune disease. We leverage Nektar’s proprietary and proven chemistry platform in the discovery and design of our new drug candidates.

Our success is rooted in four key elements:

  • Our track record reflected by a portfolio of successful approved medicines which emanated from our chemistry platform and are made available globally by our pharmaceutical partners

  • Our unique research and development pipeline of new investigational medicines in cancer and immunology

  • Our proprietary and proven science and technology approach that fuels our discovery efforts

  • Our team of dedicated scientists, clinicians and employees focused on bringing new medicines to patients with debilitating diseases

For more information, please visit www.nektar.com

Knowledge Partner
Summit Partner
Summit Partner

OncoSec Medical Incorporated is a late-stage biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body’s immune system to target and attack cancer.  OncoSec’s lead product candidate, TAVO™, enables the intratumoral delivery of DNA-based interleukin-12 (IL-12), a naturally occurring protein with immune-stimulating functions.  The technology, which employs electroporation, is designed to produce a controlled, localized expression of IL-12 in the tumor microenvironment, enabling the immune system to target and attack tumors throughout the body. TAVO has demonstrated promising anti-tumor activity in melanoma and four other cancer types both as a monotherapy and in combination with anti-PD-1 checkpoint inhibitors. TAVO is currently being evaluated in combination with KEYTRUDA® (pembrolizumab) in two ongoing KEYNOTE clinical trials – a pivotal study in anti-PD-1 checkpoint resistant metastatic melanoma and a phase 2 study in metastatic triple negative breast cancer.  In addition to TAVO, OncoSec is identifying and developing new DNA-encoded therapeutic candidates and tumor indications for use with its new Visceral Lesion Applicator, to target deep internal tumors, such as liver, lung or pancreatic cancers.

For more information, please visit www.oncosec.com

The Next-Gen Cytokine Therapeutics Summit Goes Online for 2020

The interest in the next generation of Cytokine Therapeutics has never been greater. As an industry, we cannot afford to put things on hold.

The Next-Gen Cytokine Therapeutics Summit has been completely re-engineered to deliver the best networking experience together with exciting new learning opportunities.

The Next-Gen Cytokine Therapeutics Summit Goes Online for 2020
Key Features
Interactive Learning

The agenda is purposely built to provide an engaging and interactive learning experience. Through integrated polls, dynamic discussions, Q&A with speakers, and more, you will be able to accelerate your knowledge of Next-Gen Cytokine Therapeutics faster than ever before. The ability to actively or passively be involved in these learning opportunities is yours!

Dynamic Networking

Replicate those all-important ‘water cooler’ moments through randomly assigned networking or join topic-associated discussions to find those with similar interests to you. Scroll through the entire attendee list to message your fellow attendees, schedule 1-2-1 video calls, or create your own private session rooms for group discussions. The Next-Gen Cytokine Therapeutics Summit will enable you to meet more leaders from across the industry than ever before!

Cytokine Personalised Parcipitation
Personalized Participation

The Digital Platform lets you create your own personal agenda. You can attend live sessions, take part in open networking sessions, or take a break whenever suits you. Seamlessly hop between learning and networking at any time. Look through the program and slot sessions directly into your calendar, to help fit the conference around the day job. All of this from the comfort of your own home.

With numerous immunotherapies exploiting cytokines coming down the pipeline, the timing of the Next-Gen Cytokine Therapeutics Summit is ideal and warranted. This event provides the opportunity for those who have pioneered the space and also the newcomers in the industry to get together and learn more about this dynamic and exciting field.

Kimberly Schluns, MD Anderson Cancer Center

Modulating cytokine signaling is proving to be a powerful strategy for treating complex and serious diseases. The major breakthroughs of the future will require innovative new strategies like protein design to address long-standing challenges.

The Next-Gen Cytokine Therapeutics Summit is a perfect event to bring together innovators and thought leaders in this rapidly-evolving field.It will undoubtedly be full of rich, generative, and thought-provoking discussions that will lay the groundwork for the cytokine therapeutics of tomorrow.

Carl Walkey, Neoleukin Therapeutics

With several new and exciting cytokine programs in early-stage development, but many challenges ahead, The Next-Gen Cytokine Therapeutics Summit is certain to be an invaluable event for both experts in the field and newcomers alike.

Matthew Bernett, Xencor

Speakers

Willem Overwijk
Willem Overwijk
VP of Oncology Research
Nektar Therapeutics
Willem Overwijk
VP of Oncology Research
Nektar Therapeutics

Willem Overwijk, PhD received his MS in Medical Biology from Utrecht University in the Netherlands, trained at the Surgery Branch, National Cancer Institute in Bethesda, MD and received his PhD in Biochemistry and Molecular Biology from the George Washington University in Washington, DC. He completed his postgraduate training at the Netherlands Cancer Institute in Amsterdam before accepting a faculty position at MD Anderson Cancer Center where he focused on translational research in Immuno-Oncology. In 2018 he joined Nektar Therapeutics in San Francisco as vice president of oncology research to continue working on bringing novel agents in Immuno-Oncology to patients.

Christopher Lawrence
Christopher Lawrence
VP, Development
Neumedicines
Christopher Lawrence
VP, Development
Neumedicines

Dr. Chris Lawrence, PhD, Vice President of Development at Neumedicines Inc, is an accomplished immunologist and biochemist with over 20 years of R&D experience in the life sciences industry, covering multiple biological modalities and therapeutic areas. Chris previously held positions of increasing responsibility at Xencor, Sunesis, Amgen (formerly Tularik), and Sanofi, supporting discovery through to clinical development. Chris received his PhD, while researching at the Immunology Dept, Cambridge University, UK, and his BSc from Newcastle-Upon-Tyne University, UK.

Kimberly Schluns
Kimberly Schluns
Associate Professor
MD Anderson Cancer Center
Kimberly Schluns
Associate Professor
MD Anderson Cancer Center

Dr. Kimberly Schluns is an Associate Professor in the Department Immunology at MD Anderson Cancer Center. Through her research, she seeks to better understand the mechanisms that regulate antigen-specific CD8 T cell responses and their subsequentdifferentiation into long-lived, functional memory T cells. Her lab has published numerous findings on the role of cytokines, particularly Interleukin-15, in the generation and maintenance of memory CD8 T cells. IL-15 also enhances responses by cytotoxic cells and has potent anti-tumor properties. Currently, the lab is attempting to identify mechanisms that regulate IL-15 responses in the tumor microenvironment and by IL-15 agonists used in cancer immunotherapy. Ultimately, the insights Dr. Schluns gains by unraveling these mechanisms could be used to guide development of new cancer vaccines and tumor immunotherapies.

Matthew Bernett
Matthew Bernett
Director, Protein Engineering
Xencor
Matthew Bernett
Director, Protein Engineering
Xencor

Matthew Bernett, Ph.D. is currently a Director in the Protein Engineering group at Xencor, Inc. He has been involved in all aspects of the company’s research efforts, leading to over ten programs currently in clinical development. Presently his work focuses on the design of novel and more druggable cytokine-based therapeutics, a class of drugs which has proven challenging.

Laurence Cooper
Laurence Cooper
CEO
Ziopharm
Laurence Cooper
CEO
Ziopharm

Laurence joined Ziopharm Oncology as chief executive officer in 2015 after the Company licensed technology for a non-viral approach for genetically modifying T cells from MD Anderson Cancer and the University of Minnesota. This technology is designed to reduce the cost and complexity of genetically modified T cells. Prior to joining Ziopharm, Laurence was a tenured Professor at MD Anderson with joint appointments in the Division of Pediatrics and Department of Immunology. There, he served as Section Chief of Cell Therapy at the Children’s Cancer Hospital and helped lead scientific efforts to develop new treatment approaches which pair genetic engineering with immunotherapies. He remains a visiting scientist at MD Anderson. Laurence has coauthored dozens of peer-reviewed journal articles, abstracts, and book chapters. He has initiated multiple trials under INDs infusing T cells and NK cells. He obtained his M.D. and Ph.D. degrees at Case Western Reserve University in Cleveland and he completed his training in Pediatric Oncology and Bone Marrow Transplantation at the Fred Hutchinson Cancer Research Center in Seattle.

Chris Twitty
Chris Twitty
Chief Scientific Officer
OncoSec
Chris Twitty
Chief Scientific Officer
OncoSec

Dr. Twitty brings over 20 years of experience in tumor immunology and cancer immunotherapy, including the discovery and development of OncoSec’s leading clinical immune monitoring and biomarker program.

Dr. Twitty earned his PhD from Oregon Health & Science University where his work was focused on novel tumor vaccine strategies and was awarded an American Cancer Society fellowship training grant for his post-doctoral studies in Dr. Bernard Fox’s Molecular Tumor Immunology Laboratory. After developing a pre-clinical and clinical immunological program focused on glioblastoma at Tocagen, Dr. Twitty joined Oncosec. Previously, Dr. Twitty held scientific positions of increasing responsibility at Bayer Pharmaceuticals and Cell Genesys, Inc.

Heather Losey
Heather Losey
Senior Director, Program Lead in Immuno-Oncology
Alkermes
Heather Losey
Senior Director, Program Lead in Immuno-Oncology
Alkermes

Heather Losey was trained in protein biochemistry, structure and function, with a Ph.D. from Harvard Medical School and a postdoc in the Harvard Chemistry Department.  Heather joined Wyeth in 2006 in metabolic diseases and hemophilia research before moving to Alkermes to support the expansion of biologics and oncology research.  There, Heather led the protein engineering efforts, including ALKS 4230, for which she has been program lead from inception into ongoing clinical studies.

Douglas Jones
Douglas Jones
Director, Biotherapeutic Discovery and Research
Repertoire Immune Medicines
Douglas Jones
Director, Biotherapeutic Discovery and Research
Repertoire Immune Medicines

Doug Jones, Ph.D., is a Director in Immuno-oncology Discovery and Early Development at Repertoire Immune Medicines where he leads multidisciplinary teams to discover and develop immune stimulating therapies for cancer. He has made critical contributions to discovery and development of Repertoire’s clinical-stage cell-associated IL-15 cell therapy program and leads discovery and early development of their cell-associated IL-12 cell therapy program. Prior to joining Repertoire he conducted research in the Laboratory of Systems Pharmacology at Harvard Medical School. He earned a Ph.D. in Biological Engineering from Stanford University with a focus on therapeutic protein engineering for oncology indications and completed a joint postdoctoral fellowship at MIT and Harvard University where he studied multivariate drug effects in inflammation-related disorders.

Carl Walkey
Carl Walkey
VP of Corporate Development
Neoleukin Therapeutics
Carl Walkey
VP of Corporate Development
Neoleukin Therapeutics

Carl brings scientific, product, and business development experience spanning multiple industries. Prior to joining Neoleukin Therapeutics, he served as a Senior Fellow at the Institute for Protein Design, where he led projects focused on the application of computational protein design to address unmet needs in oncology and autoimmunity. In 2014, he co-founded Ansible Marketing, which develops machine learning tools to automate omni-channel communications for small and medium businesses. Over the past decade, Dr. Walkey has co-authored over a dozen research works and received numerous prestigious scholarships and awards, including the Alexander Graham Bell Canada Graduate Scholarship and NSERC Postdoctoral Fellowship. Dr. Walkey received his PhD from the University of Toronto, where he applied machine learning to develop enhanced nanomedicines for drug delivery and vaccine development.

Fahar Merchant
Fahar Merchant
President & CEO
Medicenna
Fahar Merchant
President & CEO
Medicenna

Dr Fahar Merchant, is a 30 year biotech veteran, with a track record of building successful private and publicly listed biopharmaceutical companies. He is a co-founder, President and CEO of Medicenna Therapeutics, a clinical stage immunotherapy company developing novel, IL-2, IL-4 and IL-13 Superkines and Empowered Cytokines. Fahar studied at Aston and Birmingham Universities before completing a PhD in Biochemical Engineering at Western University.

Khaled Ali
Khaled Ali
Senior Scientist
Amgen
Khaled Ali
Senior Scientist
Amgen

Khaled Ali, Ph.D. has 10 years + experience in the field of cancer immunology, he obtained his PhD from University College London and completed post-doctoral studies at the Ludwig Institute for Cancer Research. Before joining Amgen, he was a senior fellow at the Barts Cancer Institute in London where his interests focused on understanding the role of Regulatory T cells in cancer. He is currently a Senior Scientist at Amgen, leading a group interested in understanding the molecular mechanisms that drive T cell dysfunction in cancer.

Partner With Us

The Next-Gen Cytokine Therapeutics Summit being online presents an opportunity for us to super-charge our offering. We have selected the best-in-class platform to offer our attendees a wide range of options to learn, network, and collaborate. The result, bringing together the industry leaders in cytokine therapeutics.

Making your session engaging and knowledgeable will attract the largest audience. We will guide you on how best to maximize the benefits of using our platform.

No need to sit behind a desk!  Our networking tools enable attendees to arrange 121 video conversations as well as taking part in curated networking sessions. You could potentially meet many more people than you would in a typical venue setting.

Get in touch to learn more about the options available at The Next-Gen Cytokine Therapeutics Summit.

Contact Us +
Partner With Us

Register for the Event

For pricing and booking options please click the button to go to the registration page.

Registration